Results 51 to 60 of about 1,921,670 (307)

Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment [PDF]

, 2009
Background: t(9;22) is a balanced translocation, and the chromosome 22 breakpoints (Philadelphia chromosome – Ph+) determine formation of different fusion genes that are associated with either Ph+ acute lymphatic leukemia (Ph+ ALL) or chronic myeloid ...
Xiaomin Zheng, Malcolm A S Moore, Martin Ruthardt, Ruthardt, Martin, Oancea, Claudia, Claudia Oancea, Malcolm A. S. Moore, Reinhard Henschler, Henschler, Reinhard, Moore, Malcolm A. S., Zheng, Xiaomin, Oancea Claudia, Henschler Reinhard, Moore Malcolm A. S., Ruthardt Martin, Zheng Xiaomin   +15 more
core   +2 more sources

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Haematologica, 2008
Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+ acute myeloid leukemia) shows distinctive biological and clinical features.
Arcangelo Liso, Filippo Castiglione, Antonio Cappuccio, Fabrizio Stracci, Richard F. Schlenk, Sergio Amadori, Christian Thiede, Susanne Schnittger, Peter J.M. Valk, Konstanze Döhner, Massimo F. Martelli, Markus Schaich, Jürgen Krauter, Arnold Ganser, Maria P. Martelli, Niccolò Bolli, Bob Löwenberg, Torsten Haferlach, Gerhard Ehninger, Franco Mandelli, Hartmut Döhner, Franziska Michor, Brunangelo Falini   +22 more
doaj   +1 more source

Epigenetics in Acute Myeloid Leukemia [PDF]

Seminars in Oncology, 2008
Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation of clonal neoplastic hematopoietic precursor cells. This leads to the disruption of normal hematopoiesis and bone marrow failure. Major breakthroughs in the past have contributed to our understanding of the genetic failures and the changed biology in AML cells that ...
Christoph, Plass, Christopher, Oakes, William, Blum, Guido, Marcucci   +3 more
openaire   +2 more sources

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]

, 2002
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Kottaridis, P.D., Gale, R.E., Bowen, D.T., Langabeer, S.E., Frew, M.E., Linch, D.C.   +5 more
core  

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations

Haematologica, 2014
Acute myeloid leukemia is a neoplasm characterized by recurrent molecular aberrations traditionally demonstrated by cytogenetic analyses. We used high density genome-wide genotyping and gene expression profiling to reveal acquired cryptic abnormalities ...
Saman Abbas, Mathijs A. Sanders, Annelieke Zeilemaker, Wendy M.C. Geertsma-Kleinekoort, Jasper E. Koenders, Francois G. Kavelaars, Zabiollah G. Abbas, Souad Mahamoud, Isabel W.T. Chu, Remco Hoogenboezem, Justine K. Peeters, Ellen van Drunen, Janneke van Galen, H. Berna Beverloo, Bob Löwenberg, Peter J.M. Valk   +15 more
doaj   +1 more source

Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage

Frontiers in Oncology, 2021
Acute leukemia of ambiguous lineage (ALAL) is a rare type of leukemia and represents an unmet clinical need. In fact, due to heterogeneity, substantial rarity and absence of clinical trials, there are no therapeutic guidelines available.
Gabriele Merati, Marianna Rossi, Anna Gallì, Elisa Roncoroni, Silvia Zibellini, Ettore Rizzo, Daniela Pietra, Cristina Picone, Barbara Rocca, Claudia Patricia Tobar Cabrera, Eleonora Gelli, Eugenio Santacroce, Luca Arcaini, Luca Arcaini, Patrizia Zappasodi   +14 more
doaj   +1 more source

Influence of Cytokines and Autologous Lymphokine-Activated Killer Cells on Leukemic Bone Marrow Cells and Colonies in AML [PDF]

, 2001
We have already shown that cytokine cocktails (IL-1 beta, IL-3, IL-6, SCF, GM-CSF) and/or lymphokine-activated killer (LAK) cells can reduce the amounts of clonal, CD34-positive mononuclear bone marrow cells (BM-MNC) in acute myeloid leukemia (AML).
Gerhartz, Helmut Heinrich, Schmetzer, Helga Maria, Braun, Susanne Walburg   +2 more
core   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source